Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · FRLN · as of Jun 9, 2026
Key Statistics
Explore Freeline Therapeutics Holdings plc Data
frln stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 28.6%
Competitors & Peers
frln competitorsFRLN
ALLK
ANGN
ANPC
ELEV
LMNLStock Performance
Full HistoryAbout Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage …
what is freeline therapeutics holdings plc · frln stock overview · freeline therapeutics holdings plc company profile · who is freeline therapeutics holdings plc ceo · frln NASDAQ · freeline therapeutics holdings plc headquarters · freeline therapeutics holdings plc business segments
About Stock Overview & Key Data
Freeline Therapeutics Holdings plc (FRLN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 7, 2020. As of the latest trading session, FRLN stock price is $6.49, with a market capitalization of $28.3M. The stock has returned +3.02% over the past 12 months and +1.56% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Freeline Therapeutics Holdings plc stock is Hold, with an average 12-month price target of $—. In fiscal year 2022, Freeline Therapeutics Holdings plc reported revenue of — and net income of -$89.0M. For detailed data — including Freeline Therapeutics Holdings plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Freeline Therapeutics Holdings plc (FRLN) stock price is $6.49. The stock is traded on NASDAQ under the ticker symbol FRLN. The 52-week range is $2.11 – $8.74.